Good timing on this post...
With the price rising through 70s to 80, buyout became much less likely.
Now suppose there are a few companies who did do DD on CELG. Suppose the market swoons further and pulls down CELG to low / mid 60s at which time they get EMA approval + pom filing acceptance + decent apremilast data pulling the price back up to high 60s.
You could pull trigger on 25-30% premium bid, with negotiating room in CVRs for apremilast approvals + pom approval. There's already an abraxane cvr for pancreatic. That bid would actually be a mid 80s price... so roughly 10 P/E based on 2015 #'s... in a volatile market... maybe not so far fetched??
How much did GILD pay for pharmasset again?
glta
value
